A pooled analysis investigated the prognostic role of DNA mismatch repair status in patients with stage III colon cancer treated with a standard adjuvant chemotherapy regimen. READ MORE
Important factors to consider when developing a clinical pathway for colorectal cancer.
Chemoradiotherapy and post-operative chemotherapy may be equally effective when treating patients with gastric cancer.
Lymph node ratio may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in trials.
The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer.
Systemic inflammation combined with sarcopenia could double the risk of death in patients with colorectal cancer, suggesting that these markers have clinical predictive value.
For patients with complications after colorectal surgery, being readmitted to the same medical center and being cared for by the surgeon who performed the operation may increase the likelihood of survival.
Research in Review
Patients aged 45 years or younger with colorectal cancer may have better treatment options available to them because of more mutations in their tumors than older patients.
Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery.
Patients with colorectal cancer can decrease their risk of disease-related mortality by 54% if they consume certain types of food.
Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen.